Gefitinib: current and future status in cancer therapy.

作者: Roy S. Herbst , Merrill S. Kies

DOI:

关键词:

摘要: The epidermal growth factor receptor (EGFR) is recognized as a key modulator of tumor cell function and considered to be viable drug target in range solid malignancies. Current knowledge its role progression has led newly active area anticancer research, investigating agents that the activity this receptor. Of these agents, gefitinib furthest clinical development, having received regulatory approval Japan 2002, United States Australia 2003. Gefitinib an orally active, EGFR-tyrosine kinase inhibitor blocks signal transduction pathways implicated proliferation survival cancer cells other host-dependent processes promoting growth. A plethora preclinical studies have suggested promising outcomes for agent ongoing trials wide tumors, including non-small-cell lung, head neck, colorectal, prostate, breast, either monotherapy or combination with standard chemotherapy, hormonal therapy, radiotherapy. Furthermore, biologic are specifically designed attack different progression, potential given concurrently sequentially, prevent delay disease recurrence also being investigated. This article provides detailed overview gefitinib, rationale use types, current development status novel agent.

参考文章(0)